10 Stocks Leave Wall Street Stunned

8. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive’s reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, following its terminated partnership with Novo Nordisk.

According to Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum, he was upset that Novo was feeling the pressure and was not comfortable.

“But ultimately, I think us holding strong to fighting on behalf of customers is just who we are. There’s just no way in hell we’re going to cave on that, no matter who the pharma company is or what the partnership looks like,” he noted.

Novo Nordisk terminated its partnership with Hims & Hers Health, Inc. (NYSE:HIMS), alleging the latter of failing to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of “personalization.”

Novo Nordisk also claimed that Hims & Hers Health, Inc. (NYSE:HIMS) was disseminating deceptive marketing that put patient safety at risk.